Deficiency of PTEN and CDKN2A Tumor-Suppressor Genes in Conventional and Chondroid Chordomas: Molecular Characteristics and Clinical Relevance
Chenlong Yang et al, 2020, OncoTargets and Therapy CrossRef
Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy N. L. Michmerhuizen et al, 2020, Journal of Neuro-Oncology CrossRef
HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas Daniela Jäger et al, 2017, Scientific Reports CrossRef
Recent advances in understanding and managing chordomas Carl Youssef et al, 2016, F1000Research CrossRef
Impact of silencing eEF2K expression on the malignant properties of chordoma Esra Aydemir et al, 2023, Molecular Biology Reports CrossRef
Animal model considerations for chordoma research: reproducing the tumor microenvironment in vivo with humanized mice Beatrice Campilan et al, 2024, Frontiers in Oncology CrossRef
In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts Thibault Passeri et al, 2022, Frontiers in Oncology CrossRef
Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft Thibault Passeri et al, 2022, Cancers CrossRef
From Notochord Formation to Hereditary Chordoma: The Many Roles ofBrachyury Yutaka Nibu et al, 2013, BioMed Research International CrossRef
Molecular features and vulnerabilities of recurrent chordomas Carolin Seeling et al, 2021, Journal of Experimental & Clinical Cancer Research CrossRef